Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01321892 · ClinicalTrials.gov registry record
Ex Vivo Multimodal Imaging of Upper Aerodigestive Epithelium
A clinical trial of Larynx and Squamous Cell Carcinoma of the Oral Cavity, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- 64
- Enrollment target
- 1
- Study location
NCT01321892: Completed study of Larynx and Squamous Cell Carcinoma of the Oral Cavity, sponsored by Icahn School of Medicine at Mount Sinai.
NCT01321892 is a study of Larynx and Squamous Cell Carcinoma of the Oral Cavity that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 64 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01321892, a study of Larynx and Squamous Cell Carcinoma of the Oral Cavity, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to collect information on whether images made using investigational microscopes can improve researchers' ability to evaluate and distinguish between normal and abnormal areas in tissue samples surgically removed from patients with squamous cell carcinoma. The microscopes being used in this study are considered investigational because they have not been approved by the United States Food and Drug Administration (FDA) for finding abnormal or pre-cancerous areas.
Primary Outcome
We will ask blinded raters to classify the HRME images as either benign (normal) or dysplastic/cancerous (abnormal)
Conditions Studied
Study Locations (1)
New York
- Mount Sinai School of Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2009-06 |
| Est. Completion | 2012-05 |
What the finished NCT01321892 record still lists
NCT01321892 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 64 participants, a relatively small participant target.
The record links to 4 conditions, with Larynx appearing as the primary indexed condition, and to 0 interventions.
NCT01321892 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01321892 about?
NCT01321892 is a clinical study titled "Ex Vivo Multimodal Imaging of Upper Aerodigestive Epithelium". The purpose of this research study is to collect information on whether images made using investigational microscopes can improve researchers' ability to evaluate and distinguish between normal and abnormal areas in tissue samples surgically removed from patients with squamous cell carcinoma. The mi...
What is the current status of trial NCT01321892?
This trial is currently completed. The enrollment target is 64 participants. The study started on 2009-06. Estimated completion is 2012-05.
What conditions does trial NCT01321892 study?
This clinical trial studies the following conditions: Larynx, Squamous Cell Carcinoma of the Oral Cavity, Oropharynx, Hypopharynx.
Who is sponsoring clinical trial NCT01321892?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01321892 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Larynx
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia